Key Considerations When Selecting EGFR Inhibitor Treatments in NSCLC - Episode 3

Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC

May 9, 2025

Zosia Piotrowska, MD, MHS , Martin Dietrich, MD, PhD

Panelists discuss how the overall survival benefit from the MARIPOSA regimen (amivantamab plus lazertinib) with a hazard ratio of 0.75 and projected survival improvement exceeding 1 year represents a significant advancement that must be weighed against toxicity concerns.

EP. 1: Combination Therapy: A New Frontline Standard in the Treatment of EGFR-Mutant NSCLC

EP. 2: Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective

Now Viewing

EP. 3: Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC

EP. 4: The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC

EP. 5: Disease Reassessment at First Progression and Treatment Options for Resistance Mechanisms in EGFR-mutant NSCLC

EP. 6: The Impact of Frontline Treatment Selection on Second-line Therapy for EGFR-mutant NSCLC

EP. 7: Treatment Options in the Second-Line for CNS Protection In EGFR-Mutant NSCLC

EP. 8: The Future of Biomarkers in EGFR-Mutant NSCLC: Sequencing Strategies and Optimizing Patient Time on Treatment

EP. 9: Final Thoughts on the Treatment of EGFR-Mutant NSCLC: Balancing Safety and Efficacy, and the Importance of Incorporating Supportive Care Strategies

Video content above is prompted by the following:

Overall Survival Data from MARIPOSA Trial

Key Themes:

Significant Survival Improvement: Analysis of the MARIPOSA trial showing amivantamab plus lazertinib leads to improved progression-free survival and overall survival
Statistical Impact: Overall survival hazard ratio of 0.75 with projected median overall survival exceeding 1 year
Comparison Considerations: Discussion of MARIPOSA vs FLAURA2 trial designs and outcomes

Notable Insights:

Dr Dietrich: Called the 12-plus-months overall survival improvement “very refreshing” and noted the “relatively flat trajectory as we move out further on the curve,” indicating durable benefit. He stated, “Breaking through 4 years of overall survival is one thing and...5-year landmark improvements...is also very, very significant.”
Dr Piotrowska: Emphasized caution when comparing trials, noting that MARIPOSA had “no crossover allowed” while FLAURA2 patients could access chemotherapy in later lines of treatment, making direct comparison of survival outcomes challenging.